Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.

Point-of-Care Device Compared for Cardiac Troponin Assay

By Labmedica International staff writers
Posted on 02 Oct 2013
Image: The i-STAT portable clinical analyzer system (Photo courtesy of Abbot Laboratories).
Image: The i-STAT portable clinical analyzer system (Photo courtesy of Abbot Laboratories).
A fingerstick point-of-care (POC) testing for cardiac troponin I has been compared to conventional venipuncture POC testing.

Cardiac troponin assays commonly exceed one hour while point-of-care testing can be completed in minutes by basic life support personnel so when patients present complaining of chest pain, time can be critical to achieving positive outcomes.

Scientists at the Loyola University Medical Center (Maywood, IL, USA) collected fingerstick blood samples from consenting patients for whom standard-of-care venipuncture POC troponin (POCT) testing had been ordered as part of their workup. Cardiac troponin (cTnl) assays were performed using a commercial device from June to August 2011. Eighty-nine cTnI levels were measured by both fingerstick and standard venipuncture emergency department POC testing. Four resulted in cartridge error so only the remaining 85 were analyzed.

Cardiac troponin I (cTnI) assays were performed using an i-STAT 1 device (Abbott Point of Care; Princeton, NJ, USA). Fingerstick testing, compared with standard ED POCT, has a positive predictive value of 1.00 (0.48, 1.00), a negative predictive value of 0.96 (0.89, 0.99), a sensitivity of 0.625 (0.24, 0.91), and a specificity of 1.00 (0.95, 1.00). The relationship between methods appeared to be linear.

The authors concluded that fingerstick cTnI testing using the i-STAT device is not accurate enough to determine the exact troponin level without the application of a corrective term. Fingerstick testing is, however, accurate in qualifying troponin levels as negative, borderline, or positive and is, therefore, capable of providing clinical information that may guide diagnostic and therapeutic decision-making. The study was published in the August 2013 issue of the American Journal of Emergency Medicine.

Related Links:
Loyola University Medical Center
Abbott Point of Care



KARL HECHT GMBH & CO KG
ADVANCED INSTRUMENTS
DIASYS DIAGNOSTIC SYSTEMS
WATERS CORPORATION

Channels

Genetic Tests

view channel

Overexpression of X Chromosome Genes Is Biomarker for Female Mental Disorders

A recent paper suggested that elevated expression of the genes XIST (X-inactive specific transcript) and KDM5C (lysine-specific demethylase 5C) could be used as a biological marker for diagnosis of major affective disorders in a significantly large subset of female patients from the general population. Xist is an RNA... Read more

Immunology

view channel

Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate... Read more

Industry News

view channel

Hitachi High-Tech and QIAGEN Partner to Advance Diagnostics

Hitachi High-Technologies Corporation (Tokyo, Japan) and QIAGEN N.V. (Venlo, The Netherlands) have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing. Under terms of the agreement both companies will bring their unique strengths to the collaboration:... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.